Insuman Basal Solostar

Insulin human, the active ingredient in Insuman Basal Solostar, is an insulin presented as a long‑acting injectable solution for subcutaneous use. It treats type 1 and type 2 diabetes mellitus in adults and children by providing basal insulin coverage. GNH USA supplies Insuman Basal Solostar as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Insuman Basal Solostar is a basal insulin used in the management of diabetes mellitus. - Type 1 diabetes mellitus: supplies steady basal insulin to maintain fasting glucose levels. - Type 2 diabetes mellitus: adds basal insulin when oral agents no longer achieve target glycaemia. - Insulin‑deficient states: replaces endogenous insulin to prevent hyperglycaemia and ketoacidosis.

Common Side Effects: - Hypoglycaemia: low blood glucose episodes, especially if dosing is excessive. - Injection‑site reactions: redness, swelling or itching at the injection site. - Weight gain: increased adipose tissue due to enhanced glucose utilization. - Lipodystrophy: localized changes in fat tissue with repeated injections.

Serious or Rare Side Effects: - Severe hypoglycaemia: neuroglycopenic symptoms requiring immediate assistance. - Anaphylactic reaction: rare systemic allergic response with rash, airway swelling or hypotension. - Insulin antibody formation: may alter insulin action and cause unpredictable glucose control.

Before using Insuman Basal Solostar, consider the following precautions. - Blood‑glucose monitoring: check levels regularly to adjust dose safely. - Illness or stress: may require temporary dose increase to maintain control. - Existing hypoglycaemia: avoid administration until glucose is normalized. - Renal or hepatic impairment: use with caution as clearance may be altered. - Injection technique education: rotate sites and avoid intramuscular injection. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Insuman Basal Solostar may interact with other medicines. Major Interactions (Avoid): - Sulfonylureas or meglitinides: combined use can cause severe hypoglycaemia. - Beta‑blockers: may mask hypoglycaemia symptoms, requiring closer glucose monitoring. Moderate Interactions (Monitor Closely): - ACE inhibitors or ARBs: may increase risk of hyperkalaemia when used with insulin. - Thiazide diuretics: can raise blood glucose, potentially reducing insulin effectiveness. - Corticosteroids: may increase insulin requirements due to induced hyperglycaemia.